While repackaged Avastin (bevacizumab) is in short supply, medical professional groups want the US Centers for Medicare and Medicaid Services to direct Medicare Advantage plans to suspend formulary requirements that patients “step” through off-label ocular Avastin before gaining coverage for more expensive VEGF inhibitors.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?